Table 1 Clinical characteristics, laboratory and physiological test results in all patients with IPF
|  | Median (range), n = 31 |
|---|---|
Age, years | 69 (50, 84) |
Sex, male/female | 28/3 |
Smoking, never/ex/current | 4/23/4 |
Pack-year of smoking | 35 (0, 81) |
Diagnosis, surgical lung biopsy/clinical, n | 18/13 |
Period from symptom onset, m | 49 (0, 203) |
Observation period, m | 53 (2, 205) |
%FVC before AE, % | 58.8 (37.5, 89.3) |
FEV1% before AE, % | 87.4 (78.5, 107.0) |
%DLCO before AE, % | 57.1 (33.5, 88.2) |
PaO2 at rest before AE, Torr | 70.5 (49.0, 91.0) |
6MWT distance before AE, m | 360 (160, 507) |
6MWT minSpO2 before AE, % | 82 (60, 87) |
Serum LDH at AE, ng/mL | 344 (220, 602) |
Serum KL-6 at AE, U/mL | 1367 (481, 6404) |
Serum SP-D at AE, ng/mL | 339 (23, 966) |
Extent scores on HRCT before AE (full score: 25) | 12 (7, 19) |
The GAP staging system before AE, I/II/III/unknown | 8/7/10/6 |
Preceding treatments for IPF, +/ - | 18/13 |
Preceding oxygen therapy, +/ - | 9/22 |
Period from admission to commencement of treatments for AE, day | 1 (0, 17) |
Treatment with PMX-DHP, +/- | 14/17 |
Mortality 3 months after AE, n (%) | 12 (38.7) |
Mortality 12 months after AE, n (%) | 23 (74.2) |